Claris Lifesciences Ltd.
|BSE: 533288||Sector: Health care|
|NSE: N.A.||ISIN Code: INE562G01018|
|BSE 09:19 | 14 Mar||Claris Lifesciences Ltd|
|NSE 05:30 | 01 Jan||Claris Lifesciences Ltd|
|Mkt Cap.(Rs cr)||2,161|
|Mkt Cap.(Rs cr)||2161.24|
Claris Lifesciences Ltd. (CLARISLIFESCIEN) - News Sector
8.06 am | 5 Aug 2020 | Business Standard
This sharp recovery could end up being a dead cat bounce, as the trend-line support which was recently broken could act as a resistance at 11,250
7.27 pm | 4 Aug 2020 | Press Trust of India
The Mumbai-based company has received a tentative approval from the USFDA for its Empagliflozin tablets
5.41 pm | 4 Aug 2020 | Press Trust of India
The company's strategy of developing the Specialty business as an additional growth engine has started delivering, with a gradual ramp up in specialty...
5.32 pm | 4 Aug 2020 | Business Standard
Valuations too do not leave much scope for gains
12.26 pm | 4 Aug 2020 | Business Standard
The company said it has launched the generic version of antiviral drug remdesivir in India.
10.24 am | 4 Aug 2020 | Business Standard
The UK government has also reserved one fill-and-finish production line at a Wockhardt subsidiary in Wrexham, Wales for its exclusive use for the next...
8.01 am | 4 Aug 2020 | Business Standard
The stock of Tata Consumer Products made a fresh all-time high and has provided breakout from a cup pattern on the daily chart
9.40 pm | 3 Aug 2020 | Press Trust of India
The injectable drug, under the brand name 'JUBI-R', is priced at Rs 4,700 per vial of 100 mg
9.06 pm | 3 Aug 2020 | Business Standard
Nearly 2.4 mn shares change hands at an average price of Rs 1,600.43 cr
4.26 pm | 3 Aug 2020 | Reuters
The company has reserved fill-and-finish capacity - the final manufacturing step of putting vaccines into vials or syringes and packaging them - as pa...
2.06 pm | 3 Aug 2020 | Business Standard
For the April-June, 2020 quarter, Laurus Labs posted consolidated revenue of Rs 974 crore, up 77 per cent year-on-year (YoY)
8.17 am | 3 Aug 2020 | Business Standard
For the early part of the week, 11,200-11,250 should be considered as an immediate resistance zone for Nifty.
1.28 am | 1 Aug 2020 | Business Standard
Firm's US revenue dips 33.5%; one-time loss of Rs 3,633 cr pertains to $213.3 mn pzayment by Taro, a Sun Pharma subsidiary, for settlement of anti-tru...
10.48 pm | 31 Jul 2020 | Business Standard
Equity infusion part of a larger $200-300 million round the company plans to raise over the next few months as it eyes an IPO
9.54 pm | 31 Jul 2020 | Business Standard
Chronic-heavy portfolio, pharma market recovery boost shares
4.50 pm | 31 Jul 2020 | Press Trust of India
The company had posted a net profit of Rs 1,387.48 crore for the corresponding period of the previous fiscal, Sun Pharma said in a BSE filing
11.40 am | 31 Jul 2020 | Business Standard
According to Analysts at Phillip Capital, the company's revenues could grow 18 per cent year-on-year (YoY) to Rs 1,272.5 crore in June quarter of FY21
9.58 am | 31 Jul 2020 | Business Standard
In terms of markets, while its India revenues grew marginally by 2% on a year-on-year (YoY) basis to Rs 925 crore, up from Rs 907 crore in Q1 of FY20,...
9.14 am | 31 Jul 2020 | Business Standard
Here's a list of stocks that may remain in focus today
8.01 am | 31 Jul 2020 | Business Standard
Glenmark's stock has reclaimed its short term 21-DMA